Table 3 Mutation characteristics and outcome of osimertinib treatment
From: EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
Patient | Age | Sex | Previous Systematic therapy | Previous EGFR TKI Treatment | Mutations a Before osimertinib (MAF) | Best Response | PFS |
|---|---|---|---|---|---|---|---|
1 | 63Y | F | None | None | EGFR p. A767_V769dup (3.48%) | PR | 6.0 m |
2 | 59Y | F | Yes | None | EGFR p. S768_D770dup (1.75%) | PR Treatment ongoing | 14.6 m |
3 | 69Y | M | None | None | EGFR p. N771_P772insL (47%) | SD | 4.9 m |
4 | 70Y | F | Yes | afatinib | EGFR p. S768_D770dup (3%) | SD Treatment ongoing | 11.2 m |
5 | 63Y | F | Yes | None | EGFR p. D770_N771insG (24%) | PR | 6.4 m |
6 | 65Y | F | None | gefitinib | EGFR p. A763_Y764insFQEA (0.2%) T790 M (0.3%) | PR | 5.1 m |